BioCryst to close Birmingham discovery facility; 2026 operating expense guidance lowered
BioCryst said its board approved on June 25, 2026 a plan to discontinue internal discovery programs and close its Birmingham, Alabama facility, with the work substantially complete by the end of 2026. The company cannot yet estimate the total cost of the plan and will file an amendment once it does, while lowering its 2026 non-GAAP operating expense guidance and reaffirming revenue guidance.
Key points
- Board approved the plan on June 25, 2026; implementation expected to be substantially complete by the end of 2026.
- Total costs of the plan are not yet estimated; expected costs include contract, lease and employee termination and severance.
- 2026 non-GAAP operating expense guidance lowered to $420 million to $440 million from $450 million to $470 million.
- Total 2026 revenue guidance of $635 million to $660 million is reaffirmed; ORLADEYO oral pellets expected to be available in early August 2026.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.